1. Home
  2. FOXX vs ATNM Comparison

FOXX vs ATNM Comparison

Compare FOXX & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FOXX

Foxx Development Holdings Inc.

HOLD

Current Price

$3.55

Market Cap

35.6M

Sector

N/A

ML Signal

HOLD

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

HOLD

Current Price

$0.98

Market Cap

31.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOXX
ATNM
Founded
2017
2000
Country
United States
United States
Employees
25
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.6M
31.7M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
FOXX
ATNM
Price
$3.55
$0.98
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
3.6M
136.3K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
14.17
EPS
N/A
N/A
Revenue
N/A
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.11
52 Week Low
$1.71
$0.94
52 Week High
$8.70
$1.89

Technical Indicators

Market Signals
Indicator
FOXX
ATNM
Relative Strength Index (RSI) 49.33 39.02
Support Level $2.69 $0.97
Resistance Level $4.88 $1.11
Average True Range (ATR) 0.38 0.05
MACD 0.06 0.00
Stochastic Oscillator 80.29 24.12

Price Performance

Historical Comparison
FOXX
ATNM

About FOXX Foxx Development Holdings Inc.

Foxx Development Holdings Inc is a consumer electronics and integrated Internet-of-Things (IoT) solution company catering to both retail and institutional clients. With robust research and development capabilities and a strategic commitment to cultivating long-term partnerships with mobile network operators, distributors, and suppliers. Its products include tablets, smartphones, wearables, and other high-quality communication terminals. The company's current revenue stream is derived from the sales of tablets and smartphones.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.

Share on Social Networks: